Iranian
Biomedical Journal
Volume 28, Issue 7 (Special Issue 2024)
IBJ 2024, 28(7): 200-200 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mokhtari Amirmajdi E, Moeinirad S, Boozari M. Effect of Lactobacillus reuteri on the Eradication of Helicobacter Pylori Infection. IBJ 2024; 28 (7) :200-200
URL: http://ibj.pasteur.ac.ir/article-1-4623-en.html
URL: http://ibj.pasteur.ac.ir/article-1-4623-en.html
Abstract:
Introduction: Helicobacter pylori is a Gram-negative bacterium that causes gastritis, gastric ulcers, and long-term gastrointestinal complications by producing various enzymes in the stomach. The high probability of treatment failure, caused by the rise of resistant strains and patients’ intolerance to drug side effects, has prompted to explore various strategies to enhance the effectiveness of treatment for eradication. This study aimed to evaluate the effect of adding Lactobacillus ruteri to the four-drug regimen of H. pylori.
Methods and Materials: This clinical trial study was performed on 76 patients with H. pylori infection who did not suffer from malignant or chorionic diseases or allergies to the drugs used. A simple random sampling method was used. Thirty-eight patients received probiotics, and 38 patients were in a control group with a four-drug regimen of 20 mg of omeprazole, 1000 mg of amoxicillin, 500 mg of metronidazole, and 240 mg of bismuth, all administered twice daily. The patients were followed up for two weeks at the hospitals affiliated with the Islamic Azad University of Mashhad in 2019-2020. H. pylori antigen in feces after intervention and drug side effects were assessed in all patients. Appropriate statistical tests such as variance analysis and covariance analysis were used. The data were finally analyzed using SPSS 25 software.
Results: A total of 76 patients were studied, including 46 women with a mean age of 32.30 ± 3.48 years. In the control group, there were 54 women with a mean age of 48.47 ± 13.99 years. The eradication rate of H. pylori was not significantly different between the two groups. However, the level of complications of bloating and nausea in the probiotic group was significantly lower in the case than the control group. In other complications, this rate was lower in the probiotic group but was insignificant (p > 0.05).
Conclusion and Discussion: Our findings reveled that using probiotics for H. pylori can significantly help to reduce complications during treatment; therefore, its use is recommended along with three-drug and four-drug treatments.
Methods and Materials: This clinical trial study was performed on 76 patients with H. pylori infection who did not suffer from malignant or chorionic diseases or allergies to the drugs used. A simple random sampling method was used. Thirty-eight patients received probiotics, and 38 patients were in a control group with a four-drug regimen of 20 mg of omeprazole, 1000 mg of amoxicillin, 500 mg of metronidazole, and 240 mg of bismuth, all administered twice daily. The patients were followed up for two weeks at the hospitals affiliated with the Islamic Azad University of Mashhad in 2019-2020. H. pylori antigen in feces after intervention and drug side effects were assessed in all patients. Appropriate statistical tests such as variance analysis and covariance analysis were used. The data were finally analyzed using SPSS 25 software.
Results: A total of 76 patients were studied, including 46 women with a mean age of 32.30 ± 3.48 years. In the control group, there were 54 women with a mean age of 48.47 ± 13.99 years. The eradication rate of H. pylori was not significantly different between the two groups. However, the level of complications of bloating and nausea in the probiotic group was significantly lower in the case than the control group. In other complications, this rate was lower in the probiotic group but was insignificant (p > 0.05).
Conclusion and Discussion: Our findings reveled that using probiotics for H. pylori can significantly help to reduce complications during treatment; therefore, its use is recommended along with three-drug and four-drug treatments.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
IBJ is a member of Committee on Publication Ethics (COPE)
and follows its guidelines |
The articles of this journal are licensed under
a Creative Commons Attribution-NonDerivatives 4.0 International License. .png) |
 IBJ is owned and published by Pasteur Institute of Iran |